Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters

Ajgal, Zahra; Chapuis, Nicolas; Emile, George; Cessot, Anatole; Tigaud, Jean Marie; Huillard, Olivier; Boudou‐Rouquette, Pascaline; Fontenay, Michaëla; Goldwasser, François; Alexandre, Jérôme

doi:10.1007/s00280-015-2875-8

Cited by 9 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inter‐individual variability in monocyte subpopulations was observed, representing three distinct populations with different immunological responses: classical (CD14++ CD16‐‐), non‐classical (CD14+ CD16++), and intermediate (CD14++ CD16+). While a majority displayed similar characteristics to healthy populations, two patients had lower populations of nonclassical monocytes (3.5 and 4.5 versus 10.9%) . Two others showed a decreased proportion of classical monocytes and a higher level of nonclassical and intermediate monocytes.…”

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 84%

“…This study demonstrated the association between a reduction in pre‐cycle monocyte count and decreased PLD clearance from cycles 1 to 3 of therapy ( p = 0.09) . A recent pilot study further assessed the monocyte subpopulations before PLD administration in a small patient population ( n = 9) . Inter‐individual variability in monocyte subpopulations was observed, representing three distinct populations with different immunological responses: classical (CD14++ CD16‐‐), non‐classical (CD14+ CD16++), and intermediate (CD14++ CD16+).…”

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 84%

“…23 A recent pilot study further assessed the monocyte subpopulations before PLD administration in a small patient population (n = 9). 38 Interindividual variability in monocyte subpopulations was observed, representing three distinct populations with different immunological responses: classical (CD14++ CD16--), non-classical (CD14+ CD16++), and intermediate (CD14++ CD16+). While a majority displayed similar characteristics to healthy populations, two patients had lower populations of nonclassical monocytes (3.5 and 4.5 versus 10.9%).…”

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 99%

“…While a majority displayed similar characteristics to healthy populations, two patients had lower populations of nonclassical monocytes (3.5 and 4.5 versus 10.9%). 38 Two others showed a decreased proportion of classical monocytes and a higher level of nonclassical and intermediate monocytes. These studies highlight that the MPS plays an important role in the distribution of liposomes, and potentially other CMAs.…”

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 99%

See 3 more Smart Citations

Challenges in preclinical to clinical translation for anticancer carrier‐mediated agents

Lucas

Madden

Zamboni

2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Major advances in carrier-mediated agents (CMAs), which include nanoparticles and conjugates, have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages over their small-molecule counterparts, there is substantial variability in how individual CMA formulations and patient characteristics affect the pharmacology, pharmacokinetics (PK), and pharmacodynamics (PD) (efficacy and toxicity) of these agents. Development or selection of animal models is used to predict the effects within a particular human disease. A breadth of studies have begun to emphasize the importance of preclinical animal models in understanding and evaluating the interaction between CMAs and the immune system and tumor matrix, which ultimately influences CMA PK (clearance and distribution) and PD (efficacy and toxicity). It is fundamental to study representative preclinical tumor models that recapitulate patients with diseases (e.g., cancer) and evaluate the interplay between CMAs and the immune system, including the mononuclear phagocyte system (MPS), chemokines, hormones, and other immune modulators. Furthermore, standard allometric scaling using body weight does not accurately predict drug clearance in humans. Future studies are warranted to better understand the complex pharmacology and interaction of CMA carriers within individual preclinical models and their biological systems, such as the MPS and tumor microenvironment, and their application to allometric scaling across species. WIREs Nanomed Nanobiotechnol 2016, 8:642-653. doi: 10.1002/wnan.1394 For further resources related to this article, please visit the WIREs website.

show abstract

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 84%

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 84%

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 99%

Section: The Mps In Clinical and Preclinical Modelsmentioning

confidence: 99%

See 2 more Smart Citations

Challenges in preclinical to clinical translation for anticancer carrier‐mediated agents

Lucas

Madden

Zamboni

2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…They also reported that PLD clearance is correlated with age, and a longer PLD half-life is correlated with the development of HFS [ 19 ]. Another retrospective study of 88 patients found that HFS is more common with subsequent cycles of PLD and older age [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide

Skubitz¹,

Lindgren²,

Domingo-Musibay³

et al. 2022

Cureus

View full text Add to dashboard Cite

Pegylated liposomal doxorubicin (PLD) is widely used and can be used for prolonged periods, with the limiting toxicity usually being hand-foot syndrome (HFS). The pharmacokinetics of PLD is variable between patients, leading to variability in the risk of developing HFS. Dosing based on body surface area does not decrease variability in PLD clearance; thus, other predictive markers could be useful. The peripheral blood absolute monocyte count (AMC) has been suggested as a possible marker of both reticuloendothelial system function and PLD pharmacokinetics. The present study examined the AMC as a potential predictive biomarker in a prospective trial of pre-operative PLD combined with ifosfamide in soft tissue sarcomas (STSs). While our results suggest a relationship between pre-treatment AMC and PLD-induced HFS, the association did not reach statistical significance. The clinical utility of the AMC as a predictor of PLD-induced HFS appears limited, at least when given with ifosfamide.

show abstract

Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles – The Translational Challenge

Tyson

Osae

Madden

et al. 2016

Pharmaceutical Nanotechnology: Innovation and Production

View full text Add to dashboard Cite

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters

Cited by 9 publications

References 21 publications

Challenges in preclinical to clinical translation for anticancer carrier‐mediated agents

Challenges in preclinical to clinical translation for anticancer carrier‐mediated agents

Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide

Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles – The Translational Challenge

Contact Info

Product

Resources

About